Valneva SE (VLA.VI)
| Previous Close | 3.3900 |
| Open | 3.3560 |
| Bid | 0.0000 x 50000 |
| Ask | 0.0000 x 81200 |
| Day's Range | 3.3560 - 3.4760 |
| 52 Week Range | 2.9650 - 8.0000 |
| Volume | |
| Avg. Volume | 2,590 |
| Market Cap | 483.696M |
| Beta (5Y Monthly) | 0.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript
Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript March 20, 2024 Valneva SE misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $0.2. VALN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Joshua Drumm: Thank you. Hello, and thank […]
- Insider Monkey
Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Call Transcript
Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Good day and thank you for standing by. Welcome to the Valneva 9 Months 2023 Financial Results Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Joshua Drumm, VP, Investor Relations. Please go ahead. Joshua Drumm: […]
- Reuters
FDA finds no misconduct at trial sites for Pfizer's Lyme disease shot- Care Access
The U.S. health regulator did not find any misconduct at clinical sites managed by Care Access for Pfizer and French partner Valneva's trial of a Lyme disease vaccine candidate, the contract research firm said on Wednesday. Pfizer and Valneva said in February they will stop testing the vaccine in roughly half of U.S. patients in a late-stage study, due to a breach of clinical trial guidelines by a third-party contractor. The vaccine for Lyme disease, which causes infections that are transmitted to humans through ticks, has shown a "strong immune response" in a mid-stage study in both children and adolescents a month after a booster dose.
